61040-67-3

Usage

Tertiary amine

1-methyl-(1-phenoxymethyl)ethylamine is classified as a tertiary amine because the nitrogen atom is bonded to three carbon groups, specifically a methyl group and a phenoxymethyl group.

Methyl group

A methyl group (CH3) is attached to the nitrogen atom in the compound, contributing to its structure and properties.

Phenoxymethyl group

The phenoxymethyl group (C6H4-O-CH2) is the other carbon-containing group attached to the nitrogen atom, which influences the compound's reactivity and applications.

Use in organic synthesis and chemical research

1-methyl-(1-phenoxymethyl)ethylamine serves as a building block or intermediate in the preparation of various pharmaceuticals and agrochemicals, making it valuable in these fields.

Key intermediate in dyes and fragrances production

The compound plays a crucial role in the synthesis of certain dyes and fragrances, highlighting its versatility in chemical applications.

Reagent in the formation of biologically active compounds

1-methyl-(1-phenoxymethyl)ethylamine can act as a reagent, aiding in the creation of compounds with biological activity, which can be essential in drug development and other research areas.

Synthesis of polymers

The compound is also used in the synthesis of some polymers, demonstrating its importance in material science and related industries.

Upstream product

• 167762-90-5 2-(4-chlorophenylthio)-1,1-dimethylethylamine 
• 3598-14-9 phenoxyacetonitrile 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 65933-40-6 1-[(1,1-DIMETHYL-2-PHENOXYETHYL)AMINO]-3-[4-(METHYLSULFONYL)-m-TOLYLOXY]-2-PROPANOL 
• 70959-14-7 5-[2-(1,1-Dimethyl-2-phenoxy-ethylamino)-1-hydroxy-ethyl]-2-methyl-benzenesulfonamide 

Relevant academic research and scientific papers

BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof. The compounds are inhibitors of ERK 1/2 kinases and will be useful in the treatment of ERKl/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

Imidazole derivatives as therapeutic agents

Compounds of the formula I STR1 and pharmaceutically acceptable salts thereof in which R1 represents hydrogen, halo, cyano, cyanoalkyl, alkyl, alkoxy, phenoxy, phenyl, alkoxycarbonyl, --NR13 R14, --N(R15)SO2 R16, halogenated alkoxy, halogenated alkyl, arylalkoxy, hydroxy, phenylalkyl, alkoxycarbonylvinyl, --S(O)n R7, alkoxycarbonylalkyl, carboxyalkyl, --CONR11 R12 carbamoylvinyl, --OSO2 R21, 4,5-dihydrothiazol-2-yl, 4,4-dimethyl-2-oxazolin-2-yl or --NR60 R61 ; or R1 represents a group of formula --(O)z --L3 G wherein z equals 0 or 1, L3 represents a C1-4 alkylene chain, G represents a group of formula a), b), c), or d): a) --NR22 R23 ; b) --S(O)m R26 ; c) CONR27 R28 ; d) --OR29 ; R2 and R3 independently represent hydrogen, halo, alkyl, alkoxy, --NR13 R14, halogenated alkoxy, halogenated alkyl, hydroxy, --S(O)n R7 or --NR60 R61 ; L1 represents e) a bond, or f) alkylene, cycloalkylene or cycloalkylidene; T represents a bond or O, S, SO, SO2, a carbonyl group, or 1,3-dioxolan-2-ylidene; L2 represents alkylene, cycloalkylene, or cycloalkylidene; R6 represents hydrogen or alkyl (optionally substituted by alkoxycarbonyl or hydroxy); Q represents a C1-9 alkylene chain (optionally substituted by alkyl or hydroxy); and Y represents an optionally substituted imidazole ring; which are antiinflammatory, antiallergic and immunodulant agents. Compositions containing these compounds and processes to make them are also disclosed.